Semaglutide API Batch Documentation Review: COA, HPLC, MS and NMR

Direct answer

A Semaglutide API document review should establish three things: that the material is correctly identified, that the reported batch results match the agreed specification, and that the supporting analytical records are traceable to the same batch. A Certificate of Analysis (COA) provides the batch summary, while HPLC, mass spectrometry (MS), NMR when applicable, and impurity information provide different forms of supporting evidence. These records should be reviewed together rather than treated as interchangeable certificates.

Qualified B2B buyers should begin with the exact product identity and intended project requirements. For the product currently listed by LJH Global, see Semaglutide API CAS 910463-68-2. Final specifications, document scope, packaging and regulatory suitability must be confirmed for each inquiry and buyer jurisdiction.

Confirm product identity before comparing test results

Before comparing purity values or chromatograms, confirm that every document refers to the same requested material and batch. The initial review should cover:

• product name and CAS number;
• batch or lot number;
• specification number and version;
• test date and document issue or approval date;
• material form and packaging information where stated;
• storage and transport conditions associated with the batch;
• document revision, authorization and traceability information.

A high reported purity value does not resolve an identity or traceability mismatch. If the COA, chromatogram and supporting spectra use different batch references, the buyer should request clarification before relying on the package.

How the principal records work together

The required document package depends on the project, specification and buyer quality system. The following table explains the role of the most commonly reviewed records without implying that every record is mandatory in every transaction.

Record	What it can establish	What the buyer should cross-check	Follow-up when information is unclear
COA	Batch-specific summary of tests, results and specification limits	Product identity, batch number, methods, units, acceptance criteria, actual results and authorization	Request the applicable specification or clarification of missing test items
HPLC report or chromatogram	Chromatographic purity result and the observed peak profile under the stated method	Batch number, method reference, main peak, integration, reported purity and consistency with the COA	Request the relevant method details, full chromatogram or explanation of unidentified or inconsistently reported peaks
MS data	Support for molecular mass or identity assignment	Expected and observed values, ion or charge-state interpretation, batch reference and consistency with the stated material	Request an interpretation note or additional identity evidence if the assignment is ambiguous
NMR data, when applicable	Additional structural information under the reported test conditions	Sample identity, solvent, acquisition details, interpretation and relationship to the batch under review	Clarify the purpose and scope of the NMR record rather than treating it as a routine purity test
Impurity information	Description or control of reported related substances and other relevant impurities	Naming conventions, reporting thresholds, individual and total values, method relationship and batch-to-batch pattern	Ask how unknown or atypical peaks are classified, investigated and reported
Stability or storage information	Conditions used to support handling, storage or the stated retest period	Material form, packaging configuration, temperature, protection requirements and applicable time period	Confirm whether the information applies to the exact supplied form and packaging
Batch traceability information	Connection between the supplied material, its records and shipment	Batch number across labels, COA, analytical records, packaging and commercial documents	Resolve any mismatch before shipment or internal release review

Reviewing the COA against the agreed specification

The COA should be read as a batch report, not as a substitute for the underlying specification or all supporting data. Buyers should compare the listed tests, methods, units and acceptance criteria with the specification agreed for their project. Particular attention should be paid to whether the result is an actual numerical result, a qualitative conclusion or a reference to another test record.

The review should also distinguish chromatographic purity from assay and identity. These terms answer different questions and should not be assumed to represent the same measurement. If the purchasing requirement includes a specific purity threshold, the specification, COA result and HPLC record should express that requirement consistently.

Cross-checking HPLC, MS and NMR information

HPLC is commonly used to report chromatographic purity and provide an impurity profile under a defined method. The buyer should confirm that the chromatogram belongs to the reviewed batch and that its integration and reported result correspond to the COA. A single percentage should not be assessed without the method context and peak information available for that batch.

MS supports molecular mass or identity assessment, but the displayed value may depend on the analytical method and interpretation of ions or charge states. The observed data should therefore be read together with the stated expected value and interpretation rather than compared as an isolated number.

NMR can provide additional structural information when it is part of the agreed analytical package. Its role, sample preparation and interpretation should be clear. It should not be presented as universally required for every shipment, nor should it replace batch-specific purity and identity controls performed by the applicable methods.

Evaluating impurity information and batch consistency

For peptide APIs, the value of an impurity review lies in understanding the reported profile, not merely checking whether a total value is below a limit. Buyers can compare recent batches for recurring peaks, atypical changes and consistency in reporting. Any difference should be assessed against the applicable method, specification and batch history before conclusions are drawn.

Useful follow-up questions include:

• Are individual and total impurities reported using consistent definitions?
• Are unknown or atypical peaks described or investigated when relevant?
• Does the impurity information correspond to the same HPLC method and batch?
• Are method or specification changes clearly identified between batches?
• Can the supplier explain material differences without making unsupported assumptions?

Independent or third-party testing may be included in the buyer's qualification process. Its scope should be agreed in advance so that the sample identity, methods, reporting limits and comparison criteria are clear.

Storage, packaging and shipment confirmation

Analytical review should be connected to the actual supplied material. Before shipment, qualified buyers should confirm the material form, requested quantity, packaging configuration, storage temperature, protective packaging and destination requirements. The applicable batch identifier should remain consistent across the label, quality documents and shipment records.

Storage or handling information must apply to the supplied form. Information for a prepared solution should not be substituted for conditions applicable to the unopened supplied material. Any project-specific handling requirement should be confirmed through the technical inquiry rather than inferred from a general article.

Information to include in a Semaglutide API inquiry

Providing a precise inquiry helps the supplier confirm the relevant specification and documentation package. The buyer should include:

• product name and CAS number;
• requested quantity and expected purchasing schedule;
• required purity or project-specific specification;
• material form and packaging requirements;
• destination country and requested transport conditions;
• documents or analytical records required for internal review;
• third-party testing or sample requirements, if applicable;
• intended B2B project stage and any jurisdiction-specific requirements that affect documentation.

Documentation and supply suitability are confirmed case by case. Regulatory use depends on the buyer's jurisdiction, and the buyer remains responsible for local registration, import and compliance requirements. Semaglutide API is not offered for personal use or direct consumer sale.

FAQ

Is a COA alone sufficient to evaluate a Semaglutide API batch?

The COA is the principal batch summary, but buyers may also need the applicable specification and supporting analytical records according to their internal review requirements. The required scope should be agreed for the project.

What should match between the COA and HPLC record?

At minimum, verify the product and batch identity, method reference where provided, reported chromatographic purity and the relationship between the chromatogram and the COA result.

Do purity and assay mean the same thing?

No. Chromatographic purity, assay and identity describe different analytical attributes. Buyers should review the stated method, unit and acceptance criterion for each result.

Are MS and NMR required for every Semaglutide API shipment?

Not necessarily. Their availability and purpose depend on the agreed specification, qualification stage and documentation package. Buyers should define what evidence is required rather than assume every technique is a routine release test.

How should buyers compare multiple batches?

Use the same specification and method context where possible, then compare reported purity, individual and total impurities, identity evidence, document versions and any atypical changes requiring explanation.

Can third-party testing be requested?

Third-party testing requirements can be discussed as part of a qualified B2B inquiry. The parties should confirm the sample, test scope, method, acceptance criteria and reporting format before testing begins.

What should be confirmed before requesting a quotation?

Confirm the requested quantity, specification, documentation scope, packaging, destination and transport requirements. Qualified buyers can then submit these details through the B2B inquiry page.

Related resources

• Semaglutide API product and batch document access
• Quality documentation
• Submit a B2B inquiry